Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-08-2009 | Pathology

Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection

Authors: Yukiko Shimomura, Akira Hirata, Shinichiro Ishikawa, Satoshi Okinami

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 8/2009

Abstract

Background

To examine the effects of anti-VEGF antibody (bevacizumab) on the number of fenestrations in rat choriocapillaris.

Methods

Twenty-four eyes from 24 male Wister rats were injected intravitreally with 0.125 mg of bevacizumab. The rats were perfusion fixated at 1, 3, 7, 14 or 28 days after injection. The surfaces of the choriocapillaris on the RPE side were observed using scanning electron microscopy. Four eyes treated with human IgG were used as controls. The area sieve plate and the number of fenestrations after the bevacizumab injection were measured and compared with controls.

Results

In the controls, the sieve plate area was 80.7% of the total choriocapillaris area. The number of fenestrations was 69.2 ± 0.2 /μm² of the fenestrated area. While there were no changes in the fenestrated area for any of the time points after the bevacizumab treatment, the number of fenestrations was significantly reduced to 52.9 ± 4.4 at day 1, 55.6 ± 3.6 at day 3 and 53.6 ± 8.6 /μm² of the luminal surface at day 7 (ANOVA, p < 0.05).

Conclusions

In this study, intravitreal bevacizumab injection reduced fenestration of the normal choriocapillaris. These results indicate there is a latent risk inherent with bevacizumab treatment of normal choriocapillaris.

Kvanta A, Algvere PV, Berglin L, Seregard S (1996) Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37:1929–1934PubMed

Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487. doi:10.1056/NEJM199412013312203 PubMedCrossRef

Roberts WG, Palade GE (1995) Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 108(Pt 6):2369–2379PubMed

Blaauwgeers HG, Holtkamp GM, Rutten H, Witmer AN, Koolwijk P, Partanen TA, Alitalo K, Kroon ME, Kijlstra A, van Hinsbergh VW, Schlingemann RO (1999) Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 155:421–428PubMed

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342. doi:10.1056/NEJMoa032691 PubMedCrossRef

Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U (2007) Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48:2814–2823. doi:10.1167/iovs.06–1171 PubMedCrossRef

Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336–339PubMed

Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372. doi:10.1016/j.ophtha.2005.11.019 PubMedCrossRef

Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331–335PubMed

10.

Avery RL (2006) Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26:352–354. doi:10.1097/00006982–200603000–00016 PubMedCrossRef

11.

Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695–1705. doi:10.1016/j.ophtha.2006.05.064 PubMedCrossRef

12.

Jonas JB, Harder B, Spandau UH, Kamppeter BA, Libondi T, Sauder G (2006) Bevacizumab for occult subfoveal neovascularization in age-related macular degeneration. Eur J Ophthalmol 16:774–775PubMed

13.

Shah MA, Ilson D, Kelsen DP (2005) Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 23:2574–2576. doi:10.1200/JCO.2005.81.908 PubMedCrossRef

14.

Korte GE, Reppucci V, Henkind P (1984) RPE destruction causes choriocapillary atrophy. Invest Ophthalmol Vis Sci 25:1135–1145PubMed

15.

Burns MS, Hartz MJ (1992) The retinal pigment epithelium induces fenestration of endothelial cells in vivo. Curr Eye Res 11:863–873. doi:10.3109/02713689209033484 PubMedCrossRef

16.

Marneros AG, Fan J, Yokoyama Y, Gerber HP, Ferrara N, Crouch RK, Olsen BR (2005) Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 167:1451–1459PubMed

17.

Krstić RV (1994) Human Microscopic Anatomy: An Atlas for Students of Medicine and Biology. Springer, New York

18.

Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, Schraermeyer U (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143:995–1002. doi:10.1016/j.ajo.2007.03.007 PubMedCrossRef

19.

Baluk P, Hirata A, Thurston G, Fujiwara T, Neal CR, Michel CC, McDonald DM (1997) Endothelial gaps: time course of formation and closure in inflamed venules of rats. Am J Physiol 272:L155–L170PubMed

20.

Hirata A, Baluk P, Fujiwara T, McDonald DM (1995) Location of focal silver staining at endothelial gaps in inflamed venules examined by scanning electron microscopy. Am J Physiol 269:L403–L418PubMed

21.

Korte GE, Gerszberg T, Pua F, Henkind P (1986) Choriocapillaris atrophy after experimental destruction of the retinal pigment epithelium in the rat. A study in thin sections and vascular casts. Acta Anat (Basel) 127:171–175. doi:10.1159/000146277 CrossRef

22.

Leonard DS, Zhang XG, Panozzo G, Sugino IK, Zarbin MA (1997) Clinicopathologic correlation of localized retinal pigment epithelium debridement. Invest Ophthalmol Vis Sci 38:1094–1109PubMed

23.

Ioannidou S, Deinhardt K, Miotla J, Bradley J, Cheung E, Samuelsson S, Ng Y, Shima DT (2006) An in vitro assay reveals a role for the diaphragm protein PV-1 in endothelial fenestra morphogenesis. Proc Natl Acad Sci USA 103:16770–16775. doi:10.1073/pnas.0603501103 PubMedCrossRef

24.

Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48:2545–2552. doi:10.1167/iovs.06–0570 PubMedCrossRef

25.

Barros LF, Belfort R Jr (2007) The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 79:389–394. doi:10.1590/S0001–37652007000300004 PubMed

26.

Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chevez-Barrios P (2007) Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91:804–807. doi:10.1136/bjo.2006.107912 PubMedCrossRef

27.

Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N (2008) Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 49:522–527. doi:10.1167/iovs.07–1175 PubMedCrossRef

28.

Lu F, Adelman RA (2009) Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefes Arch Clin Exp Ophthalmol 247(2):171–177PubMedCrossRef

29.

Klettner A, Roider J (2008) Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficacy and possible additional pathways. Invest Ophthalmol Vis Sci 49:4523–4527. doi:10.1167/iovs.08–2055 PubMedCrossRef

Title: Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection
Authors: Yukiko Shimomura
Akira Hirata
Shinichiro Ishikawa
Satoshi Okinami
Publication date: 01-08-2009
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 8/2009
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-009-1054-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2009

Presumed Vogt-Koyanagi-Harada disease with unilateral ocular involvement: report of three cases

Measurement of PO2 during vitrectomy for central retinal vein occlusion, a pilot study

Bestrophin detected in the basal membrane of the retinal epithelium and drusen of monkeys with drusenoid maculopathy

Optic nerve head topography in nonglaucomatous, normotensive patients with unilateral exfoliation syndrome

Diabetic patients with retinopathy show increased retinal venous oxygen saturation

Developing SDOCT to assess donor human eyes prior to tissue sectioning for research